OBJECTIVES: To determine if candidate biomarkers, ubiquitin carboxyl-terminal esterase L1 and glial fibrillary acidic protein, are elevated in neonates with hypoxic ischemic encephalopathy who die or have severe MRI injury compared with surviving infants with minimal or no injury on brain MRI. DESIGN: Prospective observational study. SETTING: Level IIIC outborn neonatal ICU in a free-standing children's hospital. PATIENTS: Term newborns with moderate-to-severe hypoxic ischemic encephalopathy referred for therapeutic hypothermia INTERVENTIONS: Serum specimens were collected at 0, 12, 24, and 72 hours of cooling. MRI was performed in surviving infants at target 7-10 days of life and was scored by a pediatric neuroradiologist masked to biomarker and clinical data. MEASUREMENTS AND MAIN RESULTS: Serial biomarker levels were determined in 20 hypoxic ischemic encephalopathy patients. Ubiquitin carboxyl-terminal esterase L1 was higher at initiation and 72 hours of cooling, while glial fibrillary acidic protein was higher at 24 and 72 hours in babies with adverse outcome compared with those with favorable outcome. CONCLUSIONS: This preliminary data support further studies to evaluate ubiquitin carboxyl-terminal esterase L1 and glial fibrillary acidic protein as immediate biomarkers of cerebral injury severity in newborns with hypoxic ischemic encephalopathy.
OBJECTIVES: To determine if candidate biomarkers, ubiquitin carboxyl-terminal esterase L1 and glial fibrillary acidic protein, are elevated in neonates with hypoxic ischemicencephalopathy who die or have severe MRI injury compared with surviving infants with minimal or no injury on brain MRI. DESIGN: Prospective observational study. SETTING: Level IIIC outborn neonatal ICU in a free-standing children's hospital. PATIENTS: Term newborns with moderate-to-severe hypoxic ischemicencephalopathy referred for therapeutic hypothermia INTERVENTIONS: Serum specimens were collected at 0, 12, 24, and 72 hours of cooling. MRI was performed in surviving infants at target 7-10 days of life and was scored by a pediatric neuroradiologist masked to biomarker and clinical data. MEASUREMENTS AND MAIN RESULTS: Serial biomarker levels were determined in 20 hypoxic ischemicencephalopathypatients. Ubiquitin carboxyl-terminal esterase L1 was higher at initiation and 72 hours of cooling, while glial fibrillary acidic protein was higher at 24 and 72 hours in babies with adverse outcome compared with those with favorable outcome. CONCLUSIONS: This preliminary data support further studies to evaluate ubiquitin carboxyl-terminal esterase L1 and glial fibrillary acidic protein as immediate biomarkers of cerebral injury severity in newborns with hypoxic ischemicencephalopathy.
Authors: Steven P Miller; Vijay Ramaswamy; David Michelson; A James Barkovich; Barbara Holshouser; Nathaniel Wycliffe; David V Glidden; Douglas Deming; J Colin Partridge; Yvonne W Wu; Stephen Ashwal; Donna M Ferriero Journal: J Pediatr Date: 2005-04 Impact factor: 4.406
Authors: L M Valentim; C B Michalowski; S P Gottardo; L Pedroso; L G Gestrich; C A Netto; C G Salbego; R Rodnight Journal: Neuroscience Date: 1999 Impact factor: 3.590
Authors: Agnes I Bartha; Audrey Foster-Barber; Steven P Miller; Daniel B Vigneron; David V Glidden; A James Barkovich; Donna M Ferriero Journal: Pediatr Res Date: 2004-10-20 Impact factor: 3.756
Authors: Seetha Shankaran; Abbot R Laptook; Richard A Ehrenkranz; Jon E Tyson; Scott A McDonald; Edward F Donovan; Avroy A Fanaroff; W Kenneth Poole; Linda L Wright; Rosemary D Higgins; Neil N Finer; Waldemar A Carlo; Shahnaz Duara; William Oh; C Michael Cotten; David K Stevenson; Barbara J Stoll; James A Lemons; Ronnie Guillet; Alan H Jobe Journal: N Engl J Med Date: 2005-10-13 Impact factor: 91.245
Authors: Namasivayam Ambalavanan; Waldemar A Carlo; Seetha Shankaran; Carla M Bann; Steven L Emrich; Rosemary D Higgins; Jon E Tyson; T Michael O'Shea; Abbot R Laptook; Richard A Ehrenkranz; Edward F Donovan; Michele C Walsh; Ronald N Goldberg; Abhik Das Journal: Pediatrics Date: 2006-11 Impact factor: 7.124
Authors: Peter D Gluckman; John S Wyatt; Denis Azzopardi; Roberta Ballard; A David Edwards; Donna M Ferriero; Richard A Polin; Charlene M Robertson; Marianne Thoresen; Andrew Whitelaw; Alistair J Gunn Journal: Lancet Date: 2005 Feb 19-25 Impact factor: 79.321
Authors: John S Wyatt; Peter D Gluckman; Ping Y Liu; Denis Azzopardi; Roberta Ballard; A David Edwards; Donna M Ferriero; Richard A Polin; Charlene M Robertson; Marianne Thoresen; Andrew Whitelaw; Alistair J Gunn Journal: Pediatrics Date: 2007-05 Impact factor: 7.124
Authors: Lina F Chalak; Pablo J Sánchez; Beverley Adams-Huet; Abbot R Laptook; Roy J Heyne; Charles R Rosenfeld Journal: J Pediatr Date: 2013-12-12 Impact factor: 4.406
Authors: An N Massaro; Taeun Chang; Stephen Baumgart; Robert McCarter; Karin B Nelson; Penny Glass Journal: Pediatr Crit Care Med Date: 2014-09 Impact factor: 3.624
Authors: A Tekes; A Poretti; M M Scheurkogel; T A G M Huisman; J A Howlett; E Alqahtani; J-H Lee; C Parkinson; K Shapiro; S-E Chung; J M Jennings; M M Gilmore; C W Hogue; L J Martin; R C Koehler; F J Northington; J K Lee Journal: AJNR Am J Neuroradiol Date: 2014-08-28 Impact factor: 3.825
Authors: Ingran Lingam; Adnan Avdic-Belltheus; Christopher Meehan; Kathryn Martinello; Sara Ragab; Donald Peebles; Melinda Barkhuizen; Cally J Tann; Ilias Tachtsidis; Tim G A M Wolfs; Henrik Hagberg; Nigel Klein; Bobbi Fleiss; Pierre Gressens; Xavier Golay; Boris W Kramer; Nicola J Robertson Journal: Pediatr Res Date: 2020-06-10 Impact factor: 3.756